Cantor Fitzgerald Reiterates “Neutral” Rating for Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies (NASDAQ:ITCI)‘s stock had its “neutral” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 0.10% from the company’s current price.

Several other analysts also recently issued reports on ITCI. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Friday, March 28th. They issued a “hold” rating on the stock. Eleven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Hold” and a consensus price target of $106.23.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI opened at $131.87 on Wednesday. The company has a 50 day moving average price of $129.53 and a two-hundred day moving average price of $101.03. Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.98. The stock has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, equities analysts anticipate that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Institutional Trading of Intra-Cellular Therapies

Institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its position in Intra-Cellular Therapies by 1.3% in the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock worth $1,614,000 after purchasing an additional 283 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Intra-Cellular Therapies by 13.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock worth $1,648,000 after acquiring an additional 2,622 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Intra-Cellular Therapies by 3.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock valued at $23,649,000 after acquiring an additional 11,104 shares in the last quarter. Captrust Financial Advisors increased its stake in Intra-Cellular Therapies by 47.0% in the third quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 2,572 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in Intra-Cellular Therapies in the third quarter valued at about $1,715,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.